Trial Profile
Phase II Study Evaluating Pharmacokinetics and Postprandial Glycemic Response of Subcutaneously Injected Humalog and Humlin R With/Without Co-Injected Recombinant Human Hyaluronidase Following Liquid Meal in Type1 Diabetes Mellitus Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin (Primary) ; Hyaluronidase; Insulin lispro
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Halozyme Therapeutics
- 02 Oct 2009 Results have been presented at EASD 2009, according to a Halozyme Therapeutics media release.
- 29 May 2009 Interim results reported at ADA 2009, as reported in a Halozyme media release.
- 19 Mar 2009 Status changed from recruiting to completed.